AMC’s stock extends losing streak to four days

Shares of AMC Entertainment Holdings Inc. ended Friday’s session down 3%, continuing the stock’s run of record lows and extending its losing streak to four days. 

The slide is AMC’s
AMC,
-2.98%
longest since a five-day losing streak that ended Jan. 5. AMC’s stock, which ended the session at $4.56, has hit a series of record-low closes recently and ended Thursday’s session at a then all-time low of $4.70. The stock’s recent performance reflects the demise of the movie-theater chain’s meme-stock status.

Related: AMC’s stock hits another record low, extends losing streak to three days

The company’s shares are down more than 98% from their all-time closing high of $339.05 on June 2, 2021, according to Dow Jones Market Data, based on available data going back to Dec. 18, 2013.

Three years ago, AMC went from a beleaguered pandemic victim to a meme-stock phenomenon. Boosted by the WallStreetBets crowd on Reddit, AMC used a steep rise in its share price to tap into equity and debt markets, raising $917 million in January 2021.

Related: This is what we can expect to see from meme stocks in 2024

The stock is currently down nine of the past 10 days and has fallen more than 12% during its four-day losing streak, according to Dow Jones Market Data.

AMC’s stock is down 89.8% in the last 52 weeks, compared with the S&P 500 index’s
SPX
gain of 19.6%.

You May Also Like

Crypto prices soar after Trump says strategic reserve will include bitcoin, XRP, Solana and others

Cryptocurrency prices surged Sunday after President Donald Trump announced certain digital assets…

Apple just gave a subtle clue that a splashy AI acquisition may be in the cards

Apple is officially retiring its net-cash-neutral target, and some suspect the iPhone…

10-, 30-year yields have biggest one-day jumps of 2025 after hot inflation data

U.S. government debt aggressively sold off on Wednesday, pushing 10-and 30-year yields…

Analyst says he’s thrown in the towel on Novo Nordisk after latest setback

Novo Nordisk’s study showing a new drug wasn’t as good as a…